We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boston Scientific Faces Challenge Reclaiming ICD Market Share
Boston Scientific Faces Challenge Reclaiming ICD Market Share
April 16, 2010
Even though Boston Scientific got the FDA’s go-ahead Thursday to resume marketing its implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators, it will have a tough time recapturing the business it lost during a month-long recall of the devices.